the secondary malignancies and cardiovascular events, may not directly relate to SCT itself.
KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia The majority of myeloproliferative neoplasms are associated with activating mutations in protein tyrosine kinase genes. 1 About 20 different fusion products of the PDGFRB gene, which encodes platelet-derived growth factor receptor-b (PDGFRb), have been described in patients with myeloid neoplasms associated with eosinophilia. 1, 2 Myelodysplastic features and thrombocytopenia are often associated with PDGFRB translocations. 3 Here, we describe a new acquired t(5;9) chromosomal translocation in a 67-year-old male patient who presented with thrombocythemia (platelets, 904 Â 10 9 /l) without prominent eosinophilia or neutrophilia. Bone marrow smears showed an increased number of polymorphic megakaryocytes without any blast cells or dysplastic features. Morphology was suggestive of myeloproliferative neoplasm, most likely essential thrombocythemia. There was no detectable BCR-ABL transcript or JAK2 V617F mutation, which is present in about 50% of patients with essential thrombocythemia. The karyotype performed on bone marrow cells showed 46,XY,t(5;9)(q31B32;p22B?24.3) in 16 of 18 metaphases ( Figure 1a ). Treatment with hydroxyurea was started, but elicited no response. After two-and-a-half months of treatment, the platelet count had increased to 1400 Â 10 9 /l and the neutrophil and eosinophil counts to 13 Â 10 9 /l and 0.9 Â 10 9 /l, respectively. The patient experienced a transient ischemic attack that was attributed to the thrombocythemia.
Fluorescence in situ hybridization analysis established the disruption of the PDGFRB locus. As this tyrosine kinase receptor is highly sensitive to imatinib mesylate, 2,3 the patient was treated with a low dose of this drug (100 mg/day). At 4 months after the initiation of this treatment, platelet and leukocyte counts were back to normal levels ( Figure 1b) . After 12 months of follow-up, the patient remains in complete hematological remission. The response to low-dose imatinib pointed to constitutive activation of PDGFRb as the cause of thrombocythemia in this patient.
Using rapid amplification of cDNA ends PCR, we identified the KANK1 gene (also called ANKRD15) on chromosome 9 as the fusion partner of PDGFRB (Figure 1c) . The fusion was confirmed by fluorescence in situ hybridization using specific KANK1 probes (Supplementary Figure S1) and by nested PCR (Figure 1d ), as described in Supplementary Materials and methods. The translocation fuses exon 2 of KANK1 (ENST00000382293, Ensembl database, up to nucleotide 3020) to exon 9 of PDGFRB (ENST00000261799, from nucleotide 1714). The junction with exon 9 of PDGFRB is unusual and was mentioned only once regarding an ETV6-PDGFRB fusion (unpublished data in Curtis et al 4 ). In line with several previously reported PDGFRb hybrids, KANK1-PDGFRb (KPb) contains three coiled-coil domains of KANK1, which may mediate the oligomerization of the hybrid protein, as shown for wild-type KANK1. 5 It also includes the fifth immunoglobulin (Ig)-like extracellular domain, the transmembrane domain and the kinase domain of PDGFRb (Figure 1e ).
The KANK1 gene was identified as a potential tumor suppressor gene at 9p24, whose expression was lost in renal cell carcinoma tissues and cell lines. The 9p chromosomal region, including KANK1, is also deleted in various cancers, such as in acute lymphocytic leukemia and in other diseases. 5 The concomitant disruption of a tumor suppressor and activation of a receptor tyrosine kinase by translocation has been suggested in other cases, such as ETV6-PDGFRB.
To assess the transforming activity of KPb, we generated lentiviral vectors expressing wild-type KANK1 or KPb and transduced the murine IL-3-dependent hematopoietic cell line Ba/F3. The KPb protein contains the first 741 residues of KANK1 fused to the last 692 residues of PDGFRb. In the absence of IL-3, only KPb-expressing cells proliferated, as shown in a [
3 H] thymidine incorporation assay (Figure 2a) . Ba/F3-KPb cells could be cultured for several weeks in the absence of IL-3 (data not shown), indicating that KPb is able to transform hematopoietic cells. To evaluate KPb sensitivity to imatinib mesylate, Ba/F3-KPb cells were exposed to increasing concentrations of the drug, which inhibited cell growth in the absence of IL-3 ( Figure 2b ). The estimated IC 50 for KPb was around 7 nM, which corresponded to the reported values for ETV6-PDGFRb and FIP1L1-PDGFRa inhibition, and is about two orders of magnitude lower than the concentration required to inhibit BCR-ABL. 2 Autophosphorylation of tyrosine residues in the intracellular part of receptor tyrosine kinases is a critical step to achieve their full activation. 2 After immunoprecipitation of PDGFRbcontaining proteins, we showed that KPb was constitutively tyrosine phosphorylated in Ba/F3 cells ( Figure 2c ). As expected, this was not observed in the presence of imatinib, suggesting that KPb phosphorylated itself. STAT transcription factors are downstream targets of the PDGF receptors.
2 Aberrant activation of STAT5 has an important role in hematopoietic cell transformation by many tyrosine kinase oncogenes, including ETV6-PDGFRB.
2 By western blot with specific anti-phospho-site antibodies, we showed that STAT5, as well as the related factor STAT3, were phosphorylated in the presence of KPb in an imatinib-dependent manner (Figure 2d) .
The uncommon breakpoint within PDGFRB found in KPb leads to the addition of the fifth Ig-like domain of the PDGFRb extracellular part to the hybrid protein. In the wild-type receptor, this domain is not implicated in ligand binding, which is mediated by the first three Ig-like domains. 2, 6 Although the function of this domain has not been fully defined, it was suggested that in c-KIT, another member of the PDGFR family, homotypic interactions between the fourth and to a lesser extent between the fifth Ig-like domains allow the intracellular part to achieve the exact position needed for the receptor activation. 6 Therefore, we investigated whether the fifth Ig-like domain could have a role in the activation of KPb. We generated a mutant devoid of this domain (DIg5) in which the PDGFRb sequence starts with exon 11, as in most of the described hybrids (Supplementary Figure S2a) . The DIg5 mutant stimulated Ba/F3 cell proliferation to a similar extent compared with KPb, suggesting no key function of this Ig-like domain in KPb activation (Supplementary Figure S2b) . Altogether, this indicated that the breakpoint in PDGFRB can be located within intron 8 or intron 10 with little impact on the activation of the protein. The higher frequency of alterations in intron 10 may be related to the size of this intron (3142 base pairs versus 1316 for intron 8).
We found no evidence of the recurrence of KANK1 rearrangement in myeloid neoplasms. In our database of B30 000 samples of patients with hematological malignancies, we found eight cases of myeloid malignancies with unexplained 9p terminal cytogenetic alterations and tested them with fluorescence in situ hybridization probes specific for the KANK1 locus. No additional case of KANK1 disruption was found. Future studies will have to search for other types of alterations in the KANK1 gene in such diseases, like deletions, mutations and epigenetic changes. Remarkably, Lerer et al. 7 suggested that KANK1 is expressed only from one allele, and is even imprinted in familial cerebral palsy. It is therefore possible that the remaining wild-type KANK1 allele is not expressed in the patient cells.
The patient presented thrombocythemia, but no prominent eosinophilia, in sharp contrast with the reported clinical features of myeloid neoplasms associated with PDGFRB rearrangements, which often include thrombocytopenia.
1,3 Therefore, we speculate that KANK1 may also have a role in the KPb-associated thrombocythemia. This is in line with a previous report by Kralovics et al., 8 indicating that KANK1 expression was decreased in polycythemia vera and essential thrombocythemia. Furthermore, KANK1 was shown to inhibit cell migration and actin polymerization through the modulation of Rho GTPases. 5 As Rho GTPases and the actin cytoskeleton have important functions during megakaryopoiesis, KANK1 might regulate thrombocyte production.
In previous reports of treatment of PDGFRb-associated myeloid neoplasms with imatinib mesylate, a daily dose of 400 mg was administered to most patients (range, 200-800 mg), in line with common practice in BCR-ABL-positive chronic myelogenous leukemia.
3
In FIP1L1-PDGFRa-positive Immunoprecipitates were separated by SDS-PAGE and blotted with an antibody against phosphorylated tyrosines (pTyr). As a control, the membrane was reprobed with an anti-PDGFR antibody. The bands shown are derived from the same blot and the same X-ray film. (d) Cells were left in cytokine-free medium for 4 h with imatinib (0.1 mM) as indicated. Cell lysates were immunoblotted with antibodies against phosphorylated or total STAT5 and STAT3. IL-3 was added for 10 min before lysis of Ba/F3. myeloproliferative neoplasm, a dose of 100 mg/day was shown to be effective. 2 As PDGFRa and b have similar sensitivity to imatinib, a low dose is likely to be effective in the treatment of PDGFRBassociated myeloid neoplasms, as suggested by the present report, with potential benefits in terms of costs and side effects.
In conclusion, we identified a new t(5;9) translocation product between PDGFRB and a novel partner, KANK1, in a patient with thrombocythemia who responded well to low-dose imatinib.
